On August 4, 2025 Tikva Allocell (Tikva), a biotechnology company developing off-the-shelf CAR-T cell therapies for solid tumors, reported that its Founder and CEO, Dr. Ivan Horak will join a keynote panel at the Asian Pharma and Biotech Project, Program and Portfolio Management Conference, being held in Singapore, August 5-6, 2025 (Press release, Tikva Allocell, AUG 4, 2025, https://www.prnewswire.com/news-releases/tikva-allocell-to-participate-in-keynote-panel-discussion-at-asian-pharma-and-biotech-project-program-and-portfolio-management-conference-302519921.html [SID1234654741]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I look forward to exploring how innovation, investment, and strategic thinking are shaping the region’s future in drug development, including advancing next generation therapies for cancer," said Dr. Horak. "Headquartered in Singapore, Tikva is led by a seasoned cell therapy development team with extensive experience in designing and developing ‘off-the-shelf’ T cell therapies utilizing Allogeneic Epstein-Barr Virus (EBV)-Specific T cells (ALLO EBVST). We look forward to discussing how Tikva is leading this next generation of CAR-T technology, and the role Singapore will play in the future of this key sector."
The panel is titled "The Evolving Pharma and Biotech Landscape in Asia, Accelerating Drug Development Through Innovation, Investment, and Strategic Growth." Panelists will discuss the state of drug development projects in Asia including key opportunities and challenges in clinical trials, R&D, and commercialization, as well as the role of incubators, government agencies, and venture funding are playing to supporting early-stage innovation and accelerate drug development. The dialogue will also elaborate on key regulatory shifts, AI, and emerging technologies and how these factors are transforming clinical development and portfolio management in Asia.
Details of the presentation are as follows:
Event:
Asian Pharma and Biotech Project, Program and Portfolio Management Conference
Date and Time:
August 5, 2025 at 9:00 AM SGT
Location:
One Farrer Hotel, Singapore
Participant:
Dr. Ivan Horak, Founder and CEO, Tikva Allocell
During the conference, Dr. Horak will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent achievements, and anticipated milestones.